Abnormal tau spread is a predominant pathological hallmark of Alzheimer’s disease and subtypes of frontotemporal dementia (FTD). It is hypothesized to contribute to disease progression and cell death. Dr. Kosik is developing a small molecule that can stop the abnormal uptake and spread of tau through the brain. This ADDF funding will support Dr. Kosik to further develop his drug. This is a novel approach for targeting tau pathology for FTD.